arrow
Y

Yukari C. Manabe

Johns Hopkins School of Medicine
H指数:53
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Adverse Drug Reactions Related to Isoniazid Preventive Therapy Among Persons Living With HIV on Dolutegravir-Based Regimens in Uganda Between July 2019 and March 2020

2019年7月至2020年3月期间,乌干达接受多替拉韦方案治疗的HIV感染者中,与异烟肼预防性治疗相关的药物不良反应

2026-04-010
PRE
Performance Evaluation of the Xpert® HCV test on Fingerstick Blood in a Prospective Observational Clinical Study at CLIA-Waived Sites in the United States

在美国CLIA豁免点进行的前瞻性观察性临床研究中,指血Xpert® HCV检测的性能评估

2026-03-130
OA
The Critical Importance of Clinical Use Case to Inform Point-of-Care Technology Development: A Case Study of Human Immunodeficiency Virus Nucleic Acid Assays in the United States

临床应用案例对指导即时检测技术开发的重大意义:美国人类免疫缺陷病毒核酸检测试剂案例研究

2025-10-010
PRE
Virology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 Sites

替诺福韦-拉米夫定-多替拉韦在初治和病毒学抑制个体中,从基于NNRTI的方案转换后的病毒学结局:一项13个中心的观察性分析

2025-07-011
OAAI
Risk Factors for Health Care-Associated Bloodstream Infections in NICUs

NICU中与医疗保健相关的血流感染的风险因素

2025-03-250
OA
Impact of cerebrospinal fluid leukocyte infiltration and activated neuroimmune mediators on survival with HIV-associated cryptococcal meningitis

脑脊液白细胞浸润和激活的神经免疫介质对HIV相关性隐球菌性脑膜炎生存的影响

2025-02-100
OAAI
The Shift to Over-the-Counter Diagnostic Testing After RADx: Clinical, Regulatory, and Societal Implications

Downing, M.; Broach, J.; Lam, W.; Manabe, Y.C.; Martin, G.; McManus, D.; Murphy, R.; Soni, A.; Schachter, S. RADx之后转向非处方诊断检测:临床、监管和社会影响。IEEE开放工程医学杂志. 2025, 6, 237–240. [谷歌学术] [交叉引用]

2025-01-010
OA
Relationship Between Acute Severe Acute Respiratory Syndrome Coronavirus 2 Viral Clearance and Long Coronavirus 2019 (Long COVID) Symptoms: A Cohort Study

急性新型冠状病毒病毒清除与长冠状病毒2019 (Long COVID) 症状之间的关系: 一项队列研究

2024-12-181
PRE
Application of machine learning algorithms to identify serological predictors of COVID-19 severity and outcomes
2024-11-260
OA